 REVIEW ARTICLE
Mark Messina et al; ONCOLOGY Vol. 27 No. 5
Recently published research questions the need for the advised restriction against the use of soyfoods by women with a history of breast cancer. • Soyfood Consumption in Breast Cancer Survivors: Don't Overstate the Facts!
• A Fitting Prescription for All: Whole Soyfoods as Part of a Varied Plant-Based Diet REVIEW ARTICLE
Rajan T. Gupta et al; ONCOLOGY Vol. 27 No. 4
Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences. • The State of Prostate MRI in 2013: Into the Breach
• Multiparametric MRI: Standardizations Needed REVIEW ARTICLE
Amelia B. Zelnak, Ruth M. O'Regan; ONCOLOGY Vol. 27 No. 3
Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. • Omics as Useful Tools in Clinical Practice: Are We There Yet?
• The Evolving Role of Multi-Gene Tests in Breast Cancer Management CONFERENCE REPORT
Cancer Network brings exclusive coverage of the annual meeting of the American Association for Cancer Research (AACR), held April 6-10, 2013 at the Walter E. Washington Convention Center in Washington, DC. This meeting brings together the best and latest findings in all major areas of cancer research. • T-DM1 Most Effective in Breast Cancer Patients With High HER2 Expression
• Triple-Negative Breast Cancer—Utilizing Biomarkers for Better Therapeutic Strategies  REVIEW ARTICLE
Matvey Tsivian, Michael R. Abern, Thomas J. Polascik; ONCOLOGY Vol. 27 No. 1
In this review we focus on the recent evolution of the concept of focal therapy and the potential applications of this management approach within an array of options currently available for patients with localized prostate cancer. • Focal Therapy: A New Active Surveillance Tool?
• Focal Therapy of Prostate Cancer—The Challenge
Don't Tell Me Anything Negative
Paul R. Helft, MD1,2,3
, May 15, 2013
I looked after one of my partner’s patients who is approaching death from advanced, refractory ovarian cancer. She asked me not to talk about anything negative with her. We can’t really make any decisions without discussing negative things. Should I just remain silent about them at her request?
Cancer Metabolism as a Therapeutic Target
Surabhi Batra, MD1,2,
Kehinde U. A. Adekola, MBBS1,
Steven T. Rosen, MD1,2,
Mala Shanmugam, PhD1,3
, May 15, 2013
Ongoing studies are attempting to understand the reasons that tumor cells engage in aerobic glycolysis in lieu of oxidative phosphorylation. In this review, we discuss known benefits to tumor cells from this metabolic switch, and we highlight key enzymes that play a role in aerobic glycolysis. We also describe novel therapeutic options targeting glucose metabolism.
• Metabolic Synthetic Lethality
• Finding the Right Target(s) in the Context of Tumor Heterogeneity, Evolution, and Metabolic Plasticity
New Targets and New Mechanisms in Lung Cancer
Daniel R. Carrizosa, MD, MS1,
Kathryn F. Mileham, MD1,
Daniel E. Haggstrom, MD1,
Gregory M. Brouse, MD1,
Raghava Induru, MD1,
Edward S. Kim, MD1
, May 15, 2013
This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.
• Lessons From Considering the Cancer Landscape
• Adapting to the Brave New World of Lung Cancer Treatment
Rising PSA Level in a 46-Year-Old Man
E. David Crawford, MD1
, May 15, 2013
A 46-year-old man sought consultation for an abnormal prostate-specific antigen (PSA) level of 9 ng/mL and one prior negative biopsy. Five months ago, while traveling, he had presented to an urgent care facility with a 24-hour history of fever, chills, nausea, and vomiting.
Advances in the Systemic Treatment of Metastatic Melanoma
Melinda Yushak, MD, MPH1,
Harriet M. Kluger, MD1,
Mario Sznol, MD1
, May 15, 2013
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.
• Treatment for Advanced Melanoma: New Drugs, New Opportunities, New Challenges
• The Past, Present, and Future of Melanoma Therapy
How the Sequester Cuts Are Harming Oncology
David Eagle, MD1,
Michael Diaz, MD2
, May 15, 2013
Now is a critical moment for all involved in caring for cancer patients to engage in this national policy debate; numerous cancer advocacy organizations have already joined the effort to oppose the sequester cuts to oncology drugs.
Introducing Three New Features
May 15, 2013
No doubt you’ve already been struck by how different the cover of this issue of ONCOLOGY looks. We hope you like our new look! More importantly, we hope you’ll like the new features we've added.
50 Shades of Pink—And Why It Helps to Know the Difference
Rebecca Bechhold, MD1
, May 17, 2013
Buy toxic chemicals and support breast cancer research! Not lying—just saw an ad on TV for weed killer and it had a pink ribbon logo on its packaging indicating, “A portion of every sale goes to support breast cancer research and awareness.” We have plenty of weed killer and a perfect lawn at our house, so I am no critic of the product. But have you noticed the pink ribbon logo on virtually every conceivable item or service?
I Can’t Talk to You With a Gun in My Face
Rebecca Bechhold, MD1
, May 3, 2013
How many times have you been killed for being the messenger with the bad news? You can often tell who is going to be angry when the CT scan shows recurrent disease. It is one of many things that are so stressful about being an oncologist. Let’s be honest; over the course of our career, we give a lot of bad news.
“This Is My Last Day on Earth”
Craig R. Hildreth, MD
, May 2, 2013
To my oncologist: You certainly were pleasant and compassionate. You also tended to minimize the gravity of the situation when my disease progressed. I know you’re not psychic, but when things are going badly, don’t be afraid to tell me you’re worried.
Conflicts of Interest in Medicine: What About Ties to Payers?
Frederic W. Grannis Jr., MD1
, April 5, 2013
Recently, the US government released new “Sunshine” standards requiring more rigorous disclosure of potential financial conflicts of interest in medicine. Such new standards are driven by revelations of misdeeds on the part of pharmaceutical and device manufacturers.
“How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
Rebecca Bechhold, MD1
, March 26, 2013
When you start seeing a patient for the first time who has been treated elsewhere and the previous oncologist has not followed standard protocol, how do you present this new way of doing things without alienating the patient or sounding critical of the previous doctor?
ONS: Infection Risk, Prevention, and Management
April 29, 2013
In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting—in both patients with solid tumors and those with hematologic malignancies.
ONS: Nurse-Physician PACT Yields Sharp Decrease in Codes
April 29, 2013
A team of nurses and physicians from Huntsman Cancer Institute successfully implemented key changes in their Patient Acute Change Team that increased nurse involvement and reduced the number of codes by 90% in the outpatient setting since they were put in place 2 years ago.
ONS: Safe Handling of Chemotherapy
April 29, 2013
Oncology nurses from a community hospital in Cincinnati, Ohio implemented a two-pronged process for the safe handling of chemotherapy, improving nurses’ satisfaction and comfort levels regarding chemotherapy safety.
ONS: Genetics and Genomics Matters
April 25, 2013
This interview covers standards for healthcare provider competency in offering comprehensive genetic services, and highlights genetics/genomics resources for nurses.
Current Challenges in Metastatic Breast Cancer: Patient Management and Treatment Strategies Interactive Case Challenge Series  This series of case presentations (five individual cases) will provide oncologists and other healthcare professionals with strategies for evaluating evidence-based data on the latest treatments in metastatic breast cancer (MBC) and the application of that data into the development of individualized approaches to care, including overcoming resistance, in order to optimize management and outcomes for patients.
Go to Activity
CancerNetwork.com offers a variety of Continuing Medical Education (CME) programs based on ONCOLOGY review articles, supplements to ONCOLOGY, textbooks, roundtable discussions, e-learning programs, and webcasts.  These interactive CME activities are offered to physicians and other healthcare professionals without charge by CME.
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
See a list of more Oncology CME activities.
Diagnostic Champions’ Challenge on Cancer Network: Designed to test the knowledge and medical diagnostic skills of physicians and other healthcare professionals, Cancer Network's Diagnostic Champions' Challenge was created to educate and entertain. Test your skills by playing… Read More»
|
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1
, May 17, 2013
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
ONS: Infection Risk, Prevention, and Management
Laura Zitella, MS, RN, ACNP-BC, AOCN1
, April 29, 2013
In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting—in both patients with solid tumors and those with hematologic malignancies.
|
